Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 121

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma89Dermatitis atopic89HIV infection78Rheumatoid arthritis75Systemic lupus erythematosus63Multiple sclerosis59Psoriasis54Psoriatic arthropathy46Myasthenia gravis44Type 1 diabetes mellitus41Systemic scleroderma40Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Sjogren's syndrome31Cardiac amyloidosis29Interstitial lung disease29Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy24Vitiligo24Hereditary angioedema22Axial spondyloarthritis21+269

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Psoriatic arthropathy

Not recruiting

Study to Predict Tofacitinib Effectiveness in Psoriatic Arthritis Patients Using Tofacitinib, Methotrexate, and Folic Acid

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Etanercept
  • Sponsor:Universitair Medisch Centrum Utrecht

Eosinophilic oesophagitis

Not recruiting

Study on Tezepelumab for Symptom Relief in Patients Aged 12-80 with Eosinophilic Esophagitis

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Crohn's disease

Not recruiting

Long-term study of upadacitinib tablets for adults with Crohn's disease

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Asthma

Not recruiting

Study on Benralizumab for Patients with Severe Asthma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study on the Effects of Riliprubart for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Type 2 diabetes mellitus+4

Not recruiting

Study on the Effects of Alendronate on Bone and Blood Sugar Markers in Patients with Diabetes and Osteopenia/Osteoporosis

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Alendronate Sodium Monohydrate
  • Sponsor:Aalborg University Hospital

Colitis ulcerative

Not recruiting

Study of Tofacitinib for Children with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Tofacitinib
  • Sponsor:Pfizer Inc.

Eosinophilic oesophagitis

Not recruiting

Study on BP1.7881 for Adults with Eosinophilic Esophagitis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BP1.7881A
  • Sponsor:Bioprojet Pharma

IgA nephropathy

Not recruiting

Study on the Effectiveness and Safety of Ravulizumab for Adults with Corticosteroid-Resistant IgA Nephropathy Flares

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre

Myasthenia gravis

Not recruiting

Study on Vimseltinib for Patients with Tenosynovial Giant Cell Tumor

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Vimseltinib
  • Sponsor:Deciphera Pharmaceuticals Inc.

HIV infection

Not recruiting

Study on the Safety and Effects of Dasatinib for Reducing Inflammation in People with HIV on Antiretroviral Therapy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dasatinib
  • Sponsor:Instituto De Investigacion En Ciencias De La Salud Germans Trias I Pujol

HIV infection

Not recruiting

Study on the Safety of Doravirine and Islatravir for HIV Patients Who Previously Participated in Doravirine/Islatravir Trials

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Doravirine
  • Sponsor:Merck Sharp & Dohme LLC

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine40 clinical trialsTenofovir Alafenamide38 clinical trialsTocilizumab38 clinical trialsMethotrexate37 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.